These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 37410975)

  • 1. Tumor Mutational Burden in Real-World Patients With Pancreatic Cancer: Genomic Alterations and Predictive Value for Immune Checkpoint Inhibitor Effectiveness.
    Quintanilha JCF; Storandt MH; Graf RP; Li G; Keller R; Lin DI; Ross JS; Huang RSP; Schrock AB; Oxnard GR; Chakrabarti S; Mahipal A
    JCO Precis Oncol; 2023 Jul; 7():e2300092. PubMed ID: 37410975
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative Effectiveness of Immune Checkpoint Inhibitors vs Chemotherapy by Tumor Mutational Burden in Metastatic Castration-Resistant Prostate Cancer.
    Graf RP; Fisher V; Weberpals J; Gjoerup O; Tierno MB; Huang RSP; Sayegh N; Lin DI; Raskina K; Schrock AB; Severson E; Haberberger JF; Ross JS; Creeden J; Levy MA; Alexander BM; Oxnard GR; Agarwal N
    JAMA Netw Open; 2022 Mar; 5(3):e225394. PubMed ID: 35357449
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Integration of comprehensive genomic profiling, tumor mutational burden, and PD-L1 expression to identify novel biomarkers of immunotherapy in non-small cell lung cancer.
    Shi Y; Lei Y; Liu L; Zhang S; Wang W; Zhao J; Zhao S; Dong X; Yao M; Wang K; Zhou Q
    Cancer Med; 2021 Apr; 10(7):2216-2231. PubMed ID: 33655698
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictive Impact of Tumor Mutational Burden on Real-World Outcomes of First-Line Immune Checkpoint Inhibition in Metastatic Melanoma.
    Andrews MC; Li G; Graf RP; Fisher VA; Mitchell J; Aboosaiedi A; O'Rourke H; Shackleton M; Iddawela M; Oxnard GR; Huang RSP
    JCO Precis Oncol; 2024 Jun; 8():e2300640. PubMed ID: 38848517
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The genetic landscape of pancreatic head ductal adenocarcinoma in China and prognosis stratification.
    Yang Y; Ding Y; Gong Y; Zhao S; Li M; Li X; Song G; Zhai B; Liu J; Shao Y; Zhu L; Pang J; Ma Y; Ou Q; Wu X; Zhang Z
    BMC Cancer; 2022 Feb; 22(1):186. PubMed ID: 35180847
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prediction of Benefit from Checkpoint Inhibitors in Mismatch Repair Deficient Metastatic Colorectal Cancer: Role of Tumor Infiltrating Lymphocytes.
    Loupakis F; Depetris I; Biason P; Intini R; Prete AA; Leone F; Lombardi P; Filippi R; Spallanzani A; Cascinu S; Bonetti LR; Maddalena G; Valeri N; Sottoriva A; Zapata L; Salmaso R; Munari G; Rugge M; Dei Tos AP; Golovato J; Sanborn JZ; Nguyen A; Schirripa M; Zagonel V; Lonardi S; Fassan M
    Oncologist; 2020 Jun; 25(6):481-487. PubMed ID: 31967692
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-Time Targeted Genome Profile Analysis of Pancreatic Ductal Adenocarcinomas Identifies Genetic Alterations That Might Be Targeted With Existing Drugs or Used as Biomarkers.
    Singhi AD; George B; Greenbowe JR; Chung J; Suh J; Maitra A; Klempner SJ; Hendifar A; Milind JM; Golan T; Brand RE; Zureikat AH; Roy S; Schrock AB; Miller VA; Ross JS; Ali SM; Bahary N
    Gastroenterology; 2019 Jun; 156(8):2242-2253.e4. PubMed ID: 30836094
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor Mutational Burden Predicting the Efficacy of Immune Checkpoint Inhibitors in Colorectal Cancer: A Systematic Review and Meta-Analysis.
    Li Y; Ma Y; Wu Z; Zeng F; Song B; Zhang Y; Li J; Lui S; Wu M
    Front Immunol; 2021; 12():751407. PubMed ID: 34659255
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genomic Profiles and Clinical Outcomes of Penile Squamous Cell Carcinoma With Elevated Tumor Mutational Burden.
    Necchi A; Spiess PE; Costa de Padua T; Li R; Grivas P; Huang RSP; Lin DI; Danziger N; Ross JS; Jacob JM; Sager RA; Basnet A; Li G; Graf RP; Pavlick DC; Bratslavsky G
    JAMA Netw Open; 2023 Dec; 6(12):e2348002. PubMed ID: 38150257
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumour mutational burden as a biomarker in patients with mismatch repair deficient/microsatellite instability-high metastatic colorectal cancer treated with immune checkpoint inhibitors.
    Manca P; Corti F; Intini R; Mazzoli G; Miceli R; Germani MM; Bergamo F; Ambrosini M; Cristarella E; Cerantola R; Boccaccio C; Ricagno G; Ghelardi F; Randon G; Leoncini G; Milione M; Fassan M; Cremolini C; Lonardi S; Pietrantonio F
    Eur J Cancer; 2023 Jul; 187():15-24. PubMed ID: 37099945
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alterations in driver genes are predictive of survival in patients with resected pancreatic ductal adenocarcinoma.
    McIntyre CA; Lawrence SA; Richards AL; Chou JF; Wong W; Capanu M; Berger MF; Donoghue MTA; Yu KH; Varghese AM; Kelsen DP; Park W; Balachandran VP; Kingham TP; D'Angelica MI; Drebin JA; Jarnagin WR; Iacobuzio-Donahue CA; Allen PJ; O'Reilly EM
    Cancer; 2020 Sep; 126(17):3939-3949. PubMed ID: 32573775
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pathogenic genomic alterations in Chinese pancreatic cancer patients and their therapeutical implications.
    Zhao Z; Li X; Wang F; Xu Y; Liu S; Han Q; Yang Z; Huang W; Yin Z; Liu Q; Tan H; Ma T; Si S; Huang J; Yuan H; Li W; Liu R
    Cancer Med; 2023 May; 12(10):11672-11685. PubMed ID: 36999792
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Utility of Tumor Mutational Burden as a Biomarker for Response to Immune Checkpoint Inhibition in the VA Population.
    Scobie MR; Zhou KI; Ahmed S; Kelley MJ
    JCO Precis Oncol; 2023 Sep; 7():e2300176. PubMed ID: 38039430
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-world pan-cancer landscape of frameshift mutations and their role in predicting responses to immune checkpoint inhibitors in cancers with low tumor mutational burden.
    Florou V; Floudas CS; Maoz A; Naqash AR; Norton C; Tan AC; Sokol ES; Frampton G; Soares HP; Puri S; Swami U; Wilky B; Hosein P; Trent J; Lopes GL; Park W; Garrido-Laguna I
    J Immunother Cancer; 2023 Aug; 11(8):. PubMed ID: 37586768
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular Characterization of KRAS Wild-type Tumors in Patients with Pancreatic Adenocarcinoma.
    Philip PA; Azar I; Xiu J; Hall MJ; Hendifar AE; Lou E; Hwang JJ; Gong J; Feldman R; Ellis M; Stafford P; Spetzler D; Khushman MM; Sohal D; Lockhart AC; Weinberg BA; El-Deiry WS; Marshall J; Shields AF; Korn WM
    Clin Cancer Res; 2022 Jun; 28(12):2704-2714. PubMed ID: 35302596
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Durable responders in advanced NSCLC with elevated TMB and treated with 1L immune checkpoint inhibitor: a real-world outcomes analysis.
    Huang RSP; Carbone DP; Li G; Schrock A; Graf RP; Zhang L; Murugesan K; Ross JS; Tolba K; Sands J; Oxnard GR; Spigel D
    J Immunother Cancer; 2023 Jan; 11(1):. PubMed ID: 36650021
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-world Validation of TMB and Microsatellite Instability as Predictive Biomarkers of Immune Checkpoint Inhibitor Effectiveness in Advanced Gastroesophageal Cancer.
    Graf RP; Fisher V; Creeden J; Schrock AB; Ross JS; Nimeiri H; Oxnard GR; Klempner SJ
    Cancer Res Commun; 2022 Sep; 2(9):1037-1048. PubMed ID: 36922935
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma.
    Qian Y; Gong Y; Fan Z; Luo G; Huang Q; Deng S; Cheng H; Jin K; Ni Q; Yu X; Liu C
    J Hematol Oncol; 2020 Oct; 13(1):130. PubMed ID: 33008426
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular characteristics of
    Seeber A; Zimmer K; Kocher F; Puccini A; Xiu J; Nabhan C; Elliott A; Goldberg RM; Grothey A; Shields AF; Battaglin F; El-Deiry WS; Philip PA; Marshall JL; Hall M; Korn WM; Lenz HJ; Wolf D; Feistritzer C; Spizzo G
    ESMO Open; 2020 Nov; 5(6):e000942. PubMed ID: 33229504
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genomic profile and clinical features of MSI-H and TMB-high pancreatic cancers: real-world data from C-CAT database.
    Sakakida T; Ishikawa T; Doi T; Morita R; Kataoka S; Miyake H; Yamaguchi K; Moriguchi M; Sogame Y; Yasuda H; Iwasaku M; Konishi H; Takayama K; Itoh Y
    J Gastroenterol; 2024 Feb; 59(2):145-156. PubMed ID: 38006445
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.